Advances and Application of a Novel Oral Anticoagulant in Specific Populations: Dabigatran Etexilate

Author(s): Delai Xu, Cujin Su, Jie Pan*

Journal Name: Current Drug Metabolism

Volume 21 , Issue 2 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Dabigatran etexilate (DE) was approved by the FDA in 2010 to reduce the risk of stroke and systemic embolism in adults with Non-valvular Atrial Fibrillation (NVAF). Compared with warfarin, a traditional anticoagulant drug, DE exhibits a shorter half-life, improved dose-effect relationship, fewer food and drug interactions, and can be taken orally without monitoring the conventional coagulation index. DE can also prevent or reduce the severity of adverse events, such as attenuated drug efficacy or bleeding. It is convenient for patients to take DE due to low levels of individual variation. This review aims to application of Dabigatran etexilate in specific populations.

Methods: Fifty-five papers were included in the review.

Results: We review the pharmacological mechanisms, pharmacokinetics and drug interactions, as well as the application of DE for different clinical populations, and provide clinical guidelines.

Conclusion: When using DE, one should consider the risk of bleeding, age, renal function, drug interactions, and other factors.

Keywords: Dabigatran etexilate, novel oral anticoagulants, pharmacokinetics, clinical trials, drug interactions, specific populations, NVAF.

[1]
Oake, N.; Jennings, A.; Forster, A.J.; Fergusson, D.; Doucette, S.; van Walraven, C. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ, 2008, 179(3), 235-244.
[http://dx.doi.org/10.1503/cmaj.080171] [PMID: 18663203]
[2]
Connolly, S.J.; Ezekowitz, M.D.; Yusuf, S.; Eikelboom, J.; Oldgren, J.; Parekh, A.; Pogue, J.; Reilly, P.A.; Themeles, E.; Varrone, J.; Wang, S.; Alings, M.; Xavier, D.; Zhu, J.; Diaz, R.; Lewis, B.S.; Darius, H.; Diener, H.C.; Joyner, C.D.; Wallentin, L. RE-LY Steering Committee and Investigators.Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 2009, 361(12), 1139-1151.
[http://dx.doi.org/10.1056/NEJMoa0905561] [PMID: 19717844]
[3]
Pollack, C.V., Jr; Reilly, P.A.; van Ryn, J.; Eikelboom, J.W.; Glund, S.; Bernstein, R.A.; Dubiel, R.; Huisman, M.V.; Hylek, E.M.; Kam, C.W.; Kamphuisen, P.W.; Kreuzer, J.; Levy, J.H.; Royle, G.; Sellke, F.W.; Stangier, J.; Steiner, T.; Verhamme, P.; Wang, B.; Young, L.; Weitz, J.I. idarucizumab for dabigatran reversal - full cohort analysis. N. Engl. J. Med., 2017, 377(5), 431-441.
[http://dx.doi.org/10.1056/NEJMoa1707278] [PMID: 28693366]
[4]
Spinler, S.A.; Shafir, V. New oral anticoagulants for atrial fibrillation. Circulation, 2012, 126(1), 133-137.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.099283] [PMID: 22753535]
[5]
Blech, S.; Ebner, T.; Ludwig-Schwellinger, E.; Stangier, J.; Roth, W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab. Dispos., 2008, 36(2), 386-399.
[http://dx.doi.org/10.1124/dmd.107.019083] [PMID: 18006647]
[6]
Stangier, J.; Clemens, A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin. Appl. Thromb. Hemost., 2009, 15(Suppl. 1), 9S-16S.
[http://dx.doi.org/10.1177/1076029609343004] [PMID: 19696042]
[7]
Reilly, P.A.; Lehr, T.; Haertter, S.; Connolly, S.J.; Yusuf, S.; Eikelboom, J.W.; Ezekowitz, M.D.; Nehmiz, G.; Wang, S.; Wallentin, L. RE-LY Investigators.The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J. Am. Coll. Cardiol., 2014, 63(4), 321-328.
[http://dx.doi.org/10.1016/j.jacc.2013.07.104] [PMID: 24076487]
[8]
Zoni-Berisso, M.; Lercari, F.; Carazza, T.; Domenicucci, S. Epidemiology of atrial fibrillation: European perspective. Clin. Epidemiol., 2014, 6, 213-220.
[http://dx.doi.org/10.2147/CLEP.S47385] [PMID: 24966695]
[9]
Eikelboom, J.W.; Connolly, S.J.; Brueckmann, M.; Granger, C.B.; Kappetein, A.P.; Mack, M.J.; Blatchford, J.; Devenny, K.; Friedman, J.; Guiver, K.; Harper, R.; Khder, Y.; Lobmeyer, M.T.; Maas, H.; Voigt, J.U.; Simoons, M.L.; Van de Werf, F. RE-ALIGN Investigators.Dabigatran versus warfarin in patients with mechanical heart valves. N. Engl. J. Med., 2013, 369(13), 1206-1214.
[http://dx.doi.org/10.1056/NEJMoa1300615] [PMID: 23991661]
[10]
Goldhaber, S.Z.; Schulman, S.; Eriksson, H.; Feuring, M.; Fraessdorf, M.; Kreuzer, J.; Schüler, E.; Schellong, S.; Kakkar, A. dabigatran versus warfarin for acute venous thromboembolism in elderly or impaired renal function patients: pooled analysis of re-cover and re-cover II. Thromb. Haemost., 2017, 117(11), 2045-2052.
[http://dx.doi.org/10.1160/TH17-03-0176] [PMID: 29202209]
[11]
Ananthapanyasut, W.; Napan, S.; Rudolph, E.H.; Harindhanavudhi, T.; Ayash, H.; Guglielmi, K.E.; Lerma, E.V. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol., 2010, 5(2), 173-181.
[http://dx.doi.org/10.2215/CJN.03170509] [PMID: 20007681]
[12]
Baber, U.; Howard, V.J.; Halperin, J.L.; Soliman, E.Z.; Zhang, X.; McClellan, W.; Warnock, D.G.; Muntner, P. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol, 2011, 4(1), 26-32.
[http://dx.doi.org/10.1161/CIRCEP.110.957100] [PMID: 21076159]
[13]
Banerjee, A.; Fauchier, L.; Vourc’h, P.; Andres, C.R.; Taillandier, S.; Halimi, J.M.; Lip, G.Y.H. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest, 2014, 145(6), 1370-1382.
[http://dx.doi.org/10.1378/chest.13-2103] [PMID: 24356875]
[14]
Olesen, J.B.; Lip, G.Y.; Kamper, A.L.; Hommel, K.; Køber, L.; Lane, D.A.; Lindhardsen, J.; Gislason, G.H.; Torp-Pedersen, C. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N. Engl. J. Med., 2012, 367(7), 625-635.
[http://dx.doi.org/10.1056/NEJMoa1105594] [PMID: 22894575]
[15]
Pisters, R.; Lane, D.A.; Nieuwlaat, R.; de Vos, C.B.; Crijns, H.J.; Lip, G.Y. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest, 2010, 138(5), 1093-1100.
[http://dx.doi.org/10.1378/chest.10-0134] [PMID: 20299623]
[16]
Camm, A.J.; Kirchhof, P.; Lip, G.Y.; Schotten, U.; Savelieva, I.; Ernst, S.; Van Gelder, I.C.; Al-Attar, N.; Hindricks, G.; Prendergast, B.; Heidbuchel, H.; Alfieri, O.; Angelini, A.; Atar, D.; Colonna, P.; De Caterina, R.; De Sutter, J.; Goette, A.; Gorenek, B.; Heldal, M.; Hohloser, S.H.; Kolh, P.; Le Heuzey, J.Y.; Ponikowski, P.; Rutten, F.H. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery.Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur. Heart J., 2010, 31(19), 2369-2429.
[http://dx.doi.org/10.1093/eurheartj/ehq278] [PMID: 20802247]
[17]
Stangier, J.; Rathgen, K.; Stähle, H.; Mazur, D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin. Pharmacokinet., 2010, 49(4), 259-268.
[http://dx.doi.org/10.2165/11318170-000000000-00000] [PMID: 20214409]
[18]
Hijazi, Z.; Hohnloser, S.H.; Oldgren, J.; Andersson, U.; Connolly, S.J.; Eikelboom, J.W.; Ezekowitz, M.D.; Reilly, P.A.; Siegbahn, A.; Yusuf, S.; Wallentin, L. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation, 2014, 129(9), 961-970.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.003628] [PMID: 24323795]
[19]
Böhm, M.; Ezekowitz, M.D.; Connolly, S.J.; Eikelboom, J.W.; Hohnloser, S.H.; Reilly, P.A.; Schumacher, H.; Brueckmann, M.; Schirmer, S.H.; Kratz, M.T.; Yusuf, S.; Diener, H.C.; Hijazi, Z.; Wallentin, L. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY Trial. J. Am. Coll. Cardiol., 2015, 65(23), 2481-2493.
[http://dx.doi.org/10.1016/j.jacc.2015.03.577] [PMID: 26065986]
[20]
Hernandez, I.; Baik, S.H.; Piñera, A.; Zhang, Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern. Med., 2015, 175(1), 18-24.
[http://dx.doi.org/10.1001/jamainternmed.2014.5398] [PMID: 25365537]
[21]
Chan, K.E.; Edelman, E.R.; Wenger, J.B.; Thadhani, R.I.; Maddux, F.W. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation, 2015, 131(11), 972-979.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.114.014113] [PMID: 25595139]
[22]
Liesenfeld, K.H.; Lehr, T.; Dansirikul, C.; Reilly, P.A.; Connolly, S.J.; Ezekowitz, M.D.; Yusuf, S.; Wallentin, L.; Haertter, S.; Staab, A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J. Thromb. Haemost., 2011, 9(11), 2168-2175.
[http://dx.doi.org/10.1111/j.1538-7836.2011.04498.x] [PMID: 21972820]
[23]
Lehr, T.; Haertter, S.; Liesenfeld, K.H.; Staab, A.; Clemens, A.; Reilly, P.A.; Friedman, J. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J. Clin. Pharmacol., 2012, 52(9), 1373-1378.
[http://dx.doi.org/10.1177/0091270011417716] [PMID: 21956604]
[24]
January, C.T.; Wann, L.S.; Alpert, J.S.; Calkins, H.; Cigarroa, J.E.; Cleveland, J.C., Jr; Conti, J.B.; Ellinor, P.T.; Ezekowitz, M.D.; Field, M.E.; Murray, K.T.; Sacco, R.L.; Stevenson, W.G.; Tchou, P.J.; Tracy, C.M.; Yancy, C.W. American College of Cardiology/American Heart Association Task Force on Practice Guidelines.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol., 2014, 64(21), e1-e76.
[http://dx.doi.org/10.1016/j.jacc.2014.03.022] [PMID: 24685669]
[25]
Zhou, Z.Q.; Hu, D.Y.; Chen, J.; Zhang, R.H.; Li, K.B.; Zhao, X.L. [An epidemiological survey of atrial fibrillation in China]. Zhonghua Nei Ke Za Zhi, 2004, 43(7), 491-494.
[PMID: 15312400]
[26]
Go, A.S.; Mozaffarian, D.; Roger, V.L.; Benjamin, E.J.; Berry, J.D.; Blaha, M.J.; Dai, S.; Ford, E.S.; Fox, C.S.; Franco, S.; Fullerton, H.J.; Gillespie, C.; Hailpern, S.M.; Heit, J.A.; Howard, V.J.; Huffman, M.D.; Judd, S.E.; Kissela, B.M.; Kittner, S.J.; Lackland, D.T.; Lichtman, J.H.; Lisabeth, L.D.; Mackey, R.H.; Magid, D.J.; Marcus, G.M.; Marelli, A.; Matchar, D.B.; McGuire, D.K.; Mohler, E.R., III; Moy, C.S.; Mussolino, M.E.; Neumar, R.W.; Nichol, G.; Pandey, D.K.; Paynter, N.P.; Reeves, M.J.; Sorlie, P.D.; Stein, J.; Towfighi, A.; Turan, T.N.; Virani, S.S.; Wong, N.D.; Woo, D.; Turner, M.B. American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation, 2014, 129(3), 399-410.
[http://dx.doi.org/10.1161/01.cir.0000442015.53336.12] [PMID: 24446411]
[27]
Lip, G.Y.; Clementy, N.; Pericart, L.; Banerjee, A.; Fauchier, L. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project. Stroke, 2015, 46(1), 143-150.
[http://dx.doi.org/10.1161/STROKEAHA.114.007199] [PMID: 25424474]
[28]
Stangier, J.; Stähle, H.; Rathgen, K.; Fuhr, R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin. Pharmacokinet., 2008, 47(1), 47-59.
[http://dx.doi.org/10.2165/00003088-200847010-00005] [PMID: 18076218]
[29]
Eikelboom, J.W.; Wallentin, L.; Connolly, S.J.; Ezekowitz, M.; Healey, J.S.; Oldgren, J.; Yang, S.; Alings, M.; Kaatz, S.; Hohnloser, S.H.; Diener, H.C.; Franzosi, M.G.; Huber, K.; Reilly, P.; Varrone, J.; Yusuf, S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation, 2011, 123(21), 2363-2372.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.110.004747] [PMID: 21576658]
[30]
Skanes, A.C.; Healey, J.S.; Cairns, J.A.; Dorian, P.; Gillis, A.M.; McMurtry, M.S.; Mitchell, L.B.; Verma, A.; Nattel, S. Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee.Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can. J. Cardiol., 2012, 28(2), 125-136.
[http://dx.doi.org/10.1016/j.cjca.2012.01.021] [PMID: 22433576]
[31]
Graham, D.J.; Reichman, M.E.; Wernecke, M.; Zhang, R.; Southworth, M.R.; Levenson, M.; Sheu, T.C.; Mott, K.; Goulding, M.R.; Houstoun, M.; MaCurdy, T.E.; Worrall, C.; Kelman, J.A. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation, 2015, 131(2), 157-164.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.114.012061] [PMID: 25359164]
[32]
Chan, P.H.; Huang, D.; Hai, J.J.; Li, W.H.; Yin, L.X.; Chan, E.W.; Wong, I.C.; Lau, C.P.; Chiang, C.E.; Zhu, J.; Tse, H.F.; Siu, C.W. Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation. Heart Rhythm, 2016, 13(2), 366-373.
[http://dx.doi.org/10.1016/j.hrthm.2015.09.015] [PMID: 26392326]
[33]
Yates, S.W. Novel oral anticoagulants for stroke prevention in atrial fibrillation: a focus on the older patient. Int. J. Gen. Med., 2013, 6, 167-180.
[http://dx.doi.org/10.2147/IJGM.S39379] [PMID: 23687449]
[34]
Barco, S.; Cheung, Y.W.; Eikelboom, J.W.; Coppens, M. New oral anticoagulants in elderly patients. Best Pract. Res. Clin. Haematol., 2013, 26(2), 215-224.
[http://dx.doi.org/10.1016/j.beha.2013.07.011] [PMID: 23953909]
[35]
James, A.H.; Jamison, M.G.; Brancazio, L.R.; Myers, E.R. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am. J. Obstet. Gynecol., 2006, 194(5), 1311-1315.
[http://dx.doi.org/10.1016/j.ajog.2005.11.008] [PMID: 16647915]
[36]
Hüttel, E.; Padberg, S.; Meister, R.; Beck, E.; Schaefer, C. Pregnancy outcome of first trimester exposure to the vitamin K antagonist phenprocoumon depends on duration of treatment. Thromb. Haemost., 2017, 117(5), 870-879.
[http://dx.doi.org/10.1160/TH16-11-0838] [PMID: 28229160]
[37]
Bapat, P.; Kedar, R.; Lubetsky, A.; Matlow, J.N.; Aleksa, K.; Berger, H.; Koren, G. Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. Obstet. Gynecol., 2014, 123(6), 1256-1261.
[http://dx.doi.org/10.1097/AOG.0000000000000277] [PMID: 24807346]
[38]
Bates, S.M.; Greer, I.A.; Middeldorp, S.; Veenstra, D.L.; Prabulos, A.M.; Vandvik, P.O. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2), e691S-e736S.
[39]
Young, G. Anticoagulation Therapies in Children. Pediatr. Clin. North Am., 2017, 64(6), 1257-1269.
[http://dx.doi.org/10.1016/j.pcl.2017.08.004] [PMID: 29173784]
[40]
Chalmers, E.; Ganesen, V.; Liesner, R.; Maroo, S.; Nokes, T.; Saunders, D.; Williams, M. British Committee for Standards in Haematology.Guideline on the investigation, management and prevention of venous thrombosis in children. Br. J. Haematol., 2011, 154(2), 196-207.
[http://dx.doi.org/10.1111/j.1365-2141.2010.08543.x] [PMID: 21595646]
[41]
von Vajna, E.; Alam, R.; So, T.Y. Current clinical trials on the use of direct oral anticoagulants in the pediatric population. current clinical trials on the use of direct oral anticoagulants in the pediatric population. Cardiol. Ther., 2016, 5(1), 19-41.
[http://dx.doi.org/10.1007/s40119-015-0054-y] [PMID: 26739579]
[42]
Halton, J.M.L.; Albisetti, M.; Biss, B.; Bomgaars, L.; Brueckmann, M.; Gropper, S.; Harper, R.; Huang, F.; Luciani, M.; Maas, H.; Tartakovsky, I.; Mitchell, L.G. Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability. J. Thromb. Haemost., 2017, 15(11), 2147-2157.
[http://dx.doi.org/10.1111/jth.13847] [PMID: 28921890]
[43]
Halton, J.M.L.; Picard, A.C.; Harper, R.; Huang, F.; Brueckmann, M.; Gropper, S.; Maas, H.; Tartakovsky, I.; Nurmeev, I.; Mitchell, L.G.; Brandão, L.R.; Chalmers, E.; Albisetti, M. Pharmacokinetics, pharmacodynamics, safety and tolerability of dabigatran etexilate oral liquid formulation in infants with venous thromboembolism. Thromb. Haemost., 2017, 117(11), 2168-2175.
[http://dx.doi.org/10.1160/TH17-06-0429] [PMID: 29202215]
[44]
Hori, M.; Connolly, S.J.; Zhu, J.; Liu, L.S.; Lau, C.P.; Pais, P.; Xavier, D.; Kim, S.S.; Omar, R.; Dans, A.L.; Tan, R.S.; Chen, J.H.; Tanomsup, S.; Watanabe, M.; Koyanagi, M.; Ezekowitz, M.D.; Reilly, P.A.; Wallentin, L.; Yusuf, S. RE-LY Investigators.Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke, 2013, 44(7), 1891-1896.
[http://dx.doi.org/10.1161/STROKEAHA.113.000990] [PMID: 23743976]
[45]
Bogatkevich, G.S.; Ludwicka-Bradley, A.; Silver, R.M. Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis Rheum., 2009, 60(11), 3455-3464.
[http://dx.doi.org/10.1002/art.24935] [PMID: 19877031]
[46]
Leask, A. Thrombin-induced CCN2 expression as a target for anti-fibrotic therapy in scleroderma. J. Cell Commun. Signal., 2010, 4(2), 111-112.
[http://dx.doi.org/10.1007/s12079-009-0082-2] [PMID: 19957054]
[47]
DeFeo, K.; Hayes, C.; Chernick, M.; Ryn, J.V.; Gilmour, S.K. Use of dabigatran etexilate to reduce breast cancer progression. Cancer Biol. Ther., 2010, 10(10), 1001-1008.
[http://dx.doi.org/10.4161/cbt.10.10.13236] [PMID: 20798593]
[48]
Paré, G.; Eriksson, N.; Lehr, T.; Connolly, S.; Eikelboom, J.; Ezekowitz, M.D.; Axelsson, T.; Haertter, S.; Oldgren, J.; Reilly, P.; Siegbahn, A.; Syvanen, A.C.; Wadelius, C.; Wadelius, M.; Zimdahl-Gelling, H.; Yusuf, S.; Wallentin, L. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation, 2013, 127(13), 1404-1412.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.001233] [PMID: 23467860]
[49]
Dimatteo, C.; D’Andrea, G.; Vecchione, G.; Paoletti, O.; Cappucci, F.; Tiscia, G.L.; Buono, M.; Grandone, E.; Testa, S.; Margaglione, M. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb. Res., 2016, 144, 1-5.
[http://dx.doi.org/10.1016/j.thromres.2016.05.025] [PMID: 27261537]
[50]
Šinigoj, P.; Malmström, R.E.; Vene, N.; Rönquist-Nii, Y.; Božič-Mijovski, M.; Pohanka, A.; Antovic, J.P.; Mavri, A. Dabigatran concentration: variability and potential bleeding prediction in “real-life” patients with atrial fibrillation. Basic Clin. Pharmacol. Toxicol., 2015, 117(5), 323-329.
[http://dx.doi.org/10.1111/bcpt.12417] [PMID: 25981948]
[51]
Stangier, J.; Eriksson, B.I.; Dahl, O.E.; Ahnfelt, L.; Nehmiz, G.; Stähle, H.; Rathgen, K.; Svärd, R. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J. Clin. Pharmacol., 2005, 45(5), 555-563.
[http://dx.doi.org/10.1177/0091270005274550] [PMID: 15831779]
[52]
Aszalos, A. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) I. Preclinical aspects. Drug Discov. Today, 2007, 12(19-20), 833-837.
[http://dx.doi.org/10.1016/j.drudis.2007.07.022] [PMID: 17933684]
[53]
Härtter, S.; Koenen-Bergmann, M.; Sharma, A.; Nehmiz, G.; Lemke, U.; Timmer, W.; Reilly, P.A. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br. J. Clin. Pharmacol., 2012, 74(3), 490-500.
[http://dx.doi.org/10.1111/j.1365-2125.2012.04218.x] [PMID: 22348256]
[54]
Walenga, J.M.; Adiguzel, C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int. J. Clin. Pract., 2010, 64(7), 956-967.
[http://dx.doi.org/10.1111/j.1742-1241.2009.02286.x] [PMID: 20584229]
[55]
Stangier, J.; Stähle, H.; Rathgen, K.; Roth, W.; Reseski, K.; Körnicke, T. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin. J. Clin. Pharmacol., 2012, 52(2), 243-250.
[http://dx.doi.org/10.1177/0091270010393342] [PMID: 21868715]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 2
Year: 2020
Page: [106 - 111]
Pages: 6
DOI: 10.2174/1389200219666181011160133
Price: $65

Article Metrics

PDF: 47
HTML: 2